This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Novo Nordisk A/S.
Reference
Johansen P, et al. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. Advances in Therapy : 11 Feb 2020. Available from: URL: http://doi.org/10.1007/s12325-020-01242-z
Rights and permissions
About this article
Cite this article
Once-weekly semaglutide good value for money in T2DM in the UK. PharmacoEcon Outcomes News 847, 22 (2020). https://doi.org/10.1007/s40274-020-6598-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6598-7